breast cancer
FDA approves Pfizer’s HRR mCRPC drug
June 21, 2023Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer
US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
AstraZeneca’s breast cancer drug given Priority Review by FDA
June 13, 2023Business Services AstraZeneca, FDA, Oncology, breast cancer
UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …
FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer
May 23, 2023Research and Development FDA, Lumicell, Oncology, breast cancer, oncology
Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New …
Polyphor’s future in question after co-primary endpoint in breast cancer study missed
June 28, 2021Sales and Marketing Primary Endpoint, breast cancer
Swiss biopharmaceutical company, Polyphor, has announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin …
Medical cannabis formulation kills breast cancer cells in trial
June 28, 2021Sales and Marketing breast cancer, medical cannabis, oncology
UK-based pharma company, Apollon Formularies, have announced that their medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) …
Novartis report longest median OS in breast cancer study
June 3, 2021Novartis, breast cancer, trials
Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …
Enhertu now available via Cancer Drugs Fund following NICE decision
April 20, 2021Manufacturing and Production AstraZeneca, breast cancer, oncology
AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …
Takeda’s breast cancer treatment approved in Scotland
February 9, 2021Manufacturing and Production Takeda, breast cancer
The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …
Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer
December 9, 2020Research and Development Kisqali, Novartis, breast cancer
Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …
University of Illinois at Chicago’s new breast cancer drug is safe and can halt disease progression, according to a Phase 1 trial
August 28, 2020Medical Communications Cancer, Cancers, breast cancer
A new breast cancer drug, called TTC-352, can halt the spread of the disease and is safe according to a …
Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer
July 29, 2020Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma
The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …
Roche’s Phesgo combo secures US approval for metastatic HER2-positive breast cancer
June 30, 2020Manufacturing and Production, Sales and Marketing FDA, Phesgo, Roche, US, breast cancer
The FDA has awarded marketing authorisation in the US to Roche’s Phesgo, a combination of subcutaneously injected Herceptin (trastuzumab) with …
NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population
May 7, 2020Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer
NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …
